# 1. Financial Performance ## A. Key Figures * **Revenue:** **₹1,065 Cr** (Q3 FY'26) (+11% YoY) * Gross Margin: 69.1% (+200 bps YoY) * Operating EBITDA: ₹305 Cr (+13% YoY) · Margin: 28.7% (+60 bps YoY) * **Net Profit:** **₹198 Cr** (+22% YoY) ## B. Revenue Growth * **Pricing & Volume Momentum:** Revenue growth underpinned by **7% price increases** and volume expansion in chronic therapies, with confidence in continued market outperformance. * **Chronic Therapy Strength:** Core growth driven by strong demand in India’s chronic portfolio, signaling resilience and brand loyalty in key therapeutic areas. ## C. Gross Margin * **Margin Expansion Drivers:** Gross margin improved significantly on favorable product mix from chronic portfolio and international CDMO/geography mix, supported by stable input costs. ## D. Operating EBITDA * **Efficiency Gains:** Operating EBITDA margin expansion reflects sustained operational discipline and leverage, with profitability growth outpacing top line. ## E. Net Profit * **Strong Bottom-Line Growth:** Net profit surged on robust operating performance and a sharp rise in **other income to ₹18 Cr** (from ₹8 Cr), fueled by treasury income post-debt repayment. --- # 2. Domestic & International Mix ## A. Key Figures * **Domestic Revenue:** **₹620 Cr** (10% YoY) * **International Revenue:** **₹445 Cr** (+12% YoY) · **Formulations: ₹306 Cr** (+20% YoY) * **Revenue Mix:** **58% Domestic** · **42% International** ## B. India Business * **Market Outperformance:** Domestic business grew at a double-digit pace YTD, consistently outpacing IPM growth by 200–300 bps, with full-year momentum expected to hold. * **Brand Strength:** J.B. Pharma ranked fastest-growing among top 25 Indian pharma companies; six domestic brands rank in top 300 with broad-based growth. * **Near-Term Moderation:** Q3–Q4 growth moderated to low-to-mid single digits due to market-wide factors, including March’s seasonally weak distributor inventory cycles. * **Franchisee Channel Resilience:** Franchisee revenues reached **₹108 Cr**, growing 11% YoY, reflecting strong channel execution and penetration. ## C. International Sales * **Robust Formulations Growth:** International segment delivered strong double-digit expansion, led by 20% growth in formulations driven by South Africa, Russia, USA, and branded exports. * **Execution & Order Book Momentum:** Q3 strength supported by carryover order book from Q2 and solid subsidiary performance; volume-driven demand remains resilient. * **Sustained Outlook:** High single-digit growth expected in Q4, in line with Q3, underpinned by continued traction in key geographies. ## D. Branded Exports * **Strategic Growth Driver:** Branded exports contributed meaningfully to international results, with positive momentum across Russia, South Africa, the U.S., and other key markets. --- # 3. Product & Therapy Performance ## A. Key Figures * **Ophthalmology Growth:** **Double-digit** YoY growth trajectory * **Ophthalmology Run Rate Target:** **₹17–18 Cr/month** within 3–4 months ## B. Chronic Portfolio * **Strong Market Outperformance:** Chronic portfolio significantly outpaces IPM, reflecting robust demand and effective market execution. * **Growth Moderation:** Overall domestic growth slightly below target due to **acute segment weakness**, particularly in the gastro portfolio. ## C. Ophthalmology Growth * **Sustained Momentum:** Ophthalmology delivers double-digit growth, led by chronic and glaucoma product strength. * **Near-Term Target:** Business on track to reach a **monthly run rate of ₹17–18 Cr** in the coming quarters, signaling scaling success. --- # 4. Segment & Business Lines ## A. Key Figures * **CDMO Revenue:** **₹117 Cr** Q3 FY'26 (flat YoY) · **₹115–120 Cr** quarterly run rate * **API Revenue:** **₹21 Cr** Q3 FY'26 ## B. Formulations * **Recovery & Growth Trajectory:** Branded generics rebounded strongly in Q3 on robust order execution, with Q4 expected to deliver double-digit growth and full-year growth in high single digits. ## C. CDMO Revenue * **Stable Performance with Growth Visibility:** CDMO maintained strong execution despite prior-year high base, driven by cost optimization and favorable product mix, with FY'27 growth guidance of **10–12%**. * **Strategic Investment:** Continued expansion in domestic operations and CDMO platform development to support scalable revenue growth and margin protection. --- # 5. Order Book & Execution ## A. Key Figures * **Gross Margin Guidance (Q4 FY'26):** **60%–69%** ## B. Q4 Visibility * **Sustained Momentum:** Sales momentum remains robust despite a high prior-year base, with strong visibility into Q4 FY'26. * **Margin Resilience:** Gross margin guidance remains healthy, supported by a strong order book and favorable execution environment. --- # 6. M&A & Integration Risks ## A. Merger Timeline * **Merger Completion:** The mergers with **Torrent** and **B. B. Chemicals and Pharmaceuticals** are both on track for expected closure in **Q4**. * **Integration Period:** Post-closure, the merger integration process is anticipated to take **6 to 9 months** before full legal and operational consolidation. ## B. Integration Delay * **Synergy Guidance Withheld:** Management refrained from providing any commentary on expected synergies, citing a preference to focus on operational performance. * **Limited Disclosure on Timing:** No rationale was offered for the 6 to 9 month gap between deal close and merger execution, with management deferring detailed process updates. --- # 7. Guidance & Outlook ## A. FY26 Margin View * **Guidance Reiterated:** Full-year operating margin outlook maintained at **27%–29%** for FY26. ## B. Q4 Growth Expectation * **International Growth on Track:** Full-year guidance for high single-digit growth in international markets remains unchanged.